Top

Published in:

01-04-2018 | Review

Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research

Authors: Victoria E. Thaney, Ana B. Sanchez, Jerel A. Fields, Arpi Minassian, Jared W. Young, Ricky Maung, Marcus Kaul

Published in: Journal of NeuroVirology | Issue 2/2018

Abstract

HIV-1 infection causes injury to the central nervous system (CNS) and is often associated with neurocognitive disorders. One model for brain damage seen in AIDS patients is the transgenic (tg) mouse expressing a soluble envelope protein gp120 of HIV-1 LAV in the brain in astrocytes under the control of the promoter of glial fibrillary acidic protein. These GFAP-gp120tg mice manifest several key neuropathological features observed in AIDS brains, such as decreased synaptic and dendritic density, increased numbers of activated microglia, and pronounced astrocytosis. Several recent studies show that brains of GFAP-gp120tg mice and neurocognitively impaired HIV patients share also a significant number of differentially regulated genes, activation of innate immunity and other cellular signaling pathways, disturbed neurogenesis, and learning deficits. These findings support the continued relevance of the GFAP-gp120tg mouse as a useful model to investigate neurodegenerative mechanisms and develop therapeutic strategies to mitigate the consequences associated with HIV infection of the CNS, neuroAIDS, and HAND.

Adle-Biassette H, Levy Y, Colombel M, Poron F, Natchev S, Keohane C, Gray F (1995) Neuronal apoptosis in HIV infection in adults. Neuropathol Appl Neurobiol 21:218–227PubMedCrossRef

Ambrose Z, Kewalramani VN, Bieniasz PD, Hatziioannou T (2007) HIV/AIDS: in search of an animal model. Trends Biotechnol 25:333–337PubMedCrossRef

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799PubMedPubMedCentralCrossRef

Asensio VC, Maier J, Milner R, Boztug K, Kincaid C, Moulard M, Phillipson C, Lindsley K, Krucker T, Fox HS, Campbell IL (2001) Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol 75:7067–7077PubMedPubMedCentralCrossRef

Avdoshina V, Fields JA, Castellano P, Dedoni S, Palchik G, Trejo M, Adame A, Rockenstein E, Eugenin E, Masliah E, Mocchetti I (2016) The HIV protein gp120 alters mitochondrial dynamics in neurons. Neurotox Res 29:583–593PubMedPubMedCentralCrossRef

Avraham HK, Jiang S, Fu Y, Rockenstein E, Makriyannis A, Zvonok A, Masliah E, Avraham S (2014) The cannabinoid CB(2) receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol 171:468–479PubMedCrossRef

Avraham HK, Jiang S, Fu Y, Rockenstein E, Makriyannis A, Wood J, Wang L, Masliah E, Avraham S (2015) Impaired neurogenesis by HIV-1-Gp120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme. Br J Pharmacol 172:4603–4614PubMedPubMedCentralCrossRef

Bachis A, Aden SA, Nosheny RL, Andrews PM, Mocchetti I (2006) Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J Neurosci 26:6771–6780PubMedCrossRef

Bachis A, Forcelli P, Masliah E, Campbell L, Mocchetti I (2016) Expression of gp120 in mice evokes anxiety behavior: co-occurrence with increased dendritic spines and brain-derived neurotrophic factor in the amygdala. Brain Behav Immun 54:170–177PubMedPubMedCentralCrossRef

Bae M, Patel N, Xu H, Lee M, Tominaga-Yamanaka K, Nath A, Geiger J, Gorospe M, Mattson MP, Haughey NJ (2014) Activation of TRPML1 clears intraneuronal Abeta in preclinical models of HIV infection. J Neurosci 34:11485–11503PubMedPubMedCentralCrossRef

Bandaru VV, Patel N, Ewaleifoh O, Haughey NJ (2011) A failure to normalize biochemical and metabolic insults during morphine withdrawal disrupts synaptic repair in mice transgenic for HIV-gp120. J NeuroImmune Pharmacol 6:640–649PubMedPubMedCentralCrossRef

Banerjee S, Liao L, Russo R, Nakamura T, McKercher SR, Okamoto S, Haun F, Nikzad R, Zaidi R, Holland E, Eroshkin A, Yates JR III, Lipton SA (2012) Isobaric tagging-based quantification by mass spectrometry of differentially regulated proteins in synaptosomes of HIV/gp120 transgenic mice: implications for HIV-associated neurodegeneration. Exp Neurol 236:298–306PubMedPubMedCentralCrossRef

Barber SA, Herbst DS, Bullock BT, Gama L, Clements JE (2004) Innate immune responses and control of acute simian immunodeficiency virus replication in the central nervous system. J Neuro-Oncol 10(Suppl 1):15–20

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868–871PubMedCrossRef

Berrada F, Ma D, Michaud J, Doucet G, Giroux L, Kessous-Elbaz A (1995) Neuronal expression of human immunodeficiency virus type 1 env proteins in transgenic mice: distribution in the central nervous system and pathological alterations. J Virol 69:6770–6778PubMedPubMedCentral

Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G (2009) Neurodegeneration and ageing in the HAART era. J NeuroImmune Pharmacol 4:163–174PubMedCrossRef

Brew BJ, Robertson K, Wright EJ, Churchill M, Crowe SM, Cysique LA, Deeks S, Garcia JV, Gelman B, Gray LR, Johnson T, Joseph J, Margolis DM, Mankowski JL, Spencer B (2015) HIV eradication symposium: will the brain be left behind? J Neuro-Oncol 21:322–334

Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Reid R, Xu R, Nath A, Knapp PE, Hauser KF (2008) Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 56:1414–1427PubMedPubMedCentralCrossRef

Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I (2006) Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 10:185–190PubMedCrossRef

Chang SL, Connaghan KP, Wei Y, Li MD (2014) NeuroHIV and use of addictive substances. Int Rev Neurobiol 118:403–440PubMedCrossRef

Chatterjee N, Callen S, Seigel GM, Buch SJ (2011) HIV-1 Tat-mediated neurotoxicity in retinal cells. J NeuroImmune Pharmacol 6:399–408PubMedPubMedCentralCrossRef

Churchill M, Nath A (2013). Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS. 8:165–169

Clements JE, Anderson MG, Zink MC, Joag SV, Narayan O (1994) The SIV model of AIDS encephalopathy. Role of neurotropic viruses in diseases. Res Publ Assoc Res Nerv Ment Dis 72:147–157PubMed

Clements JE, Mankowski JL, Gama L, Zink MC (2008) The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neuro-Oncol 14:309–317

Crews L, Ruf R, Patrick C, Dumaop W, Trejo-Morales M, Achim CL, Rockenstein E, Masliah E (2011) Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: implications for neurodegenerative disorders. Mol Neurodegener 6:67PubMedPubMedCentralCrossRef

D'hooge R, Franck F, Mucke L, De Deyn PP (1999) Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur J Neurosci 11:4398–4402PubMedCrossRef

Dash PK, Gorantla S, Gendelman HE, Knibbe J, Casale GP, Makarov E, Epstein AA, Gelbard HA, Boska MD, Poluektova LY (2011) Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci 31:3148–3157PubMedPubMedCentralCrossRef

Doyle T, Goujon C, Malim MH (2015) HIV-1 and interferons: who’s interfering with whom? Nat Rev Microbiol 13:403–413PubMedCrossRef

Ferretti F, Gisslen M, Cinque P, Price RW (2015) Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV/AIDS Rep 12:280–288PubMedCrossRef

Fields J, Dumaop W, Langford TD, Rockenstein E, Masliah E (2014) Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders. J NeuroImmune Pharmacol 9:102–116PubMedPubMedCentralCrossRef

Fields J, Dumaop W, Rockenstein E, Mante M, Spencer B, Grant I, Ellis R, Letendre S, Patrick C, Adame A, Masliah E (2013) Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. J Neuro-Oncol 19:89–101

Fields JA, Overk C, Adame A, Florio J, Mante M, Pineda A, Desplats P, Rockenstein E, Achim C, Masliah E (2016a) Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. J Neuroinflammation 13:120PubMedPubMedCentralCrossRef

Fields JA, Serger E, Campos S, Divakaruni AS, Kim C, Smith K, Trejo M, Adame A, Spencer B, Rockenstein E, Murphy AN, Ellis RJ, Letendre S, Grant I, Masliah E (2016b) HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiol Dis 86:154–169PubMedCrossRef

Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, Knapp PE, Hauser KF (2010) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177:1397–1410PubMedPubMedCentralCrossRef

Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D'Emilia DM, Friedlander RM, Yuan J, Masliah E, Lipton SA (2002) Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22:4015–4024PubMedCrossRef

Gardner MB, Luciw PA (1989) Animal models of AIDS. FASEB J 3:2593–2606PubMedCrossRef

Giulian D, Vaca K, Noonan CA (1990) Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250:1593–1596PubMedCrossRef

Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5:69–81PubMedCrossRef

Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ (2014) Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS 9:552–558PubMedPubMedCentralCrossRef

Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19:407–411PubMedCrossRef

Hahn BH, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-Staal F (1984) Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature 312:166–169PubMedCrossRef

Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, Jolicoeur P (1998a) Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol 72:121–132PubMedPubMedCentral

Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P (1998b) Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95:163–175PubMedCrossRef

Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, Nath A, Bruce-Keller AJ, Knapp PE (2009) HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia 57:194–206PubMedPubMedCentralCrossRef

Henry BL, Geyer MA, Buell M, Perry W, Young JW, Minassian A, Translational Methamphetamine ARCG (2013) Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav Brain Res 236:210–220PubMedCrossRef

Henry BL, Geyer MA, Buell MR, Perry W, Young JW, Minassian A, Translational Methamphetamine ARCG (2014) Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav Pharmacol 25:12–22PubMedPubMedCentralCrossRef

Hoefer MM, Sanchez AB, Maung R, de Rozieres CM, Catalan IC, Dowling CC, Thaney VE, Pina-Crespo J, Zhang D, Roberts AJ, Kaul M (2015) Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263:221–234PubMedCrossRef

Iwakura Y, Shioda T, Tosu M, Yoshida E, Hayashi M, Nagata T, Shibuta H (1992) The induction of cataracts by HIV-1 in transgenic mice. AIDS 6:1069–1075PubMedCrossRef

Jacobson S, Henriksen SJ, Prospero-Garcia O, Phillips TR, Elder JH, Young WG, Bloom FE, Fox HS (1997) Cortical neuronal cytoskeletal changes associated with FIV infection. J Neuro-Oncol 3:283–289

Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C (2007) HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 27:3703–3711PubMedCrossRef

Joseph J (2015) Eradication of HIV-1 from CNS reservoirs: current strategies and future priorities. J Neuro-Oncol 21:219–221

Kang YJ, Digicaylioglu M, Russo R, Kaul M, Achim CL, Fletcher L, Masliah E, Lipton SA (2010) Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann Neurol 68:342–352PubMedPubMedCentralCrossRef

Kapadia F, Vlahov D, Donahoe RM, Friedland G (2005) The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 41:1027–1034PubMedCrossRef

Kaul M (2008) HIV’s double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci 13:2484–2494PubMedPubMedCentralCrossRef

Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988–994PubMedCrossRef

Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA (2007) HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ 14:296–305PubMedCrossRef

Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH (2009) Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460:515–519PubMedPubMedCentralCrossRef

Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA (2002) Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med 195:719–736PubMedPubMedCentralCrossRef

Kesby JP, Heaton RK, Young JW, Umlauf A, Woods SP, Letendre SL, Markou A, Grant I, Semenova S (2015a) Methamphetamine exposure combined with HIV-1 disease or gp120 expression: comparison of learning and executive functions in humans and mice. Neuropsychopharmacology 40:1899–1909PubMedPubMedCentralCrossRef

Kesby JP, Hubbard DT, Markou A, Semenova S (2014). Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict Biol 19:593–605

Kesby JP, Markou A, Semenova S, Translational Methamphetamine ARCG (2015b) Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. Eur Neuropsychopharmacol 25:141–150PubMedCrossRef

Keswani SC, Jack C, Zhou C, Hoke A (2006) Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci 26:10299–10304PubMedCrossRef

Kim BO, Liu Y, Ruan Y, ZC X, Schantz L, He JJ (2003) Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162:1693–1707PubMedPubMedCentralCrossRef

Kitai R, Zhao ML, Zhang N, Hua LL, Lee SC (2000) Role of MIP-1beta and RANTES in HIV-1 infection of microglia: inhibition of infection and induction by IFNbeta. J Neuroimmunol 110:230–239PubMedCrossRef

Klotman PE, Notkins AL (1996) Transgenic models of human immunodeficiency virus type-1. Curr Top Microbiol Immunol 206:197–222PubMed

Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R (2005) Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111:194–213PubMedCrossRef

Krathwohl MD, Kaiser JL (2004) HIV-1 promotes quiescence in human neural progenitor cells. J Infect Dis 190:216–226PubMedCrossRef

Krucker T, Toggas SM, Mucke L, Siggins GR (1998) Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience 83:691–700PubMedCrossRef

Lambotte O, Deiva K, Tardieu M (2003) HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 13:95–103PubMedCrossRef

Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D, Major EO (2004) Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 78:7319–7328PubMedPubMedCentralCrossRef

Lee MH, Amin ND, Venkatesan A, Wang T, Tyagi R, Pant HC, Nath A (2013) Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation. J Neuro-Oncol 19:418–431

Lee MH, Wang T, Jang MH, Steiner J, Haughey N, Ming GL, Song H, Nath A, Venkatesan A (2011) Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease. Neurobiol Dis 41:678–687PubMedCrossRef

Leonard JM, Abramczuk JW, Pezen DS, Rutledge R, Belcher JH, Hakim F, Shearer G, Lamperth L, Travis W, Fredrickson T (1988) Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science 242:1665–1670PubMedCrossRef

Limoges J, Persidsky Y, Poluektova L, Rasmussen J, Ratanasuwan W, Zelivyanskaya M, McClernon DR, Lanier ER, Gendelman HE (2000) Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology 54:379–389PubMedCrossRef

Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL (2010) HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J NeuroImmune Pharmacol 5:294–309PubMedPubMedCentralCrossRef

Marshall DC, Wyss-Coray T, Abraham CR (1998) Induction of matrix metalloproteinase-2 in human immunodeficiency virus-1 glycoprotein 120 transgenic mouse brains. Neurosci Lett 254:97–100PubMedCrossRef

Masliah E, Westland CE, Rockenstein EM, Abraham CR, Mallory M, Veinberg I, Sheldon E, Mucke L (1997) Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience 78:135–146PubMedCrossRef

Mattson MP, Haughey NJ, Nath A (2005) Cell death in HIV dementia. Cell Death Differ 12(Suppl 1):893–904PubMedCrossRef

Maung R, Hoefer MM, Sanchez AB, Sejbuk NE, Medders KE, Desai MK, Catalan IC, Dowling CC, de Rozieres CM, Garden GA, Russo R, Roberts AJ, Williams R, Kaul M (2014) CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J Immunol 193:1895–1910PubMedPubMedCentralCrossRef

Meeker RB, Thiede BA, Hall C, English R, Tompkins M (1997) Cortical cell loss in asymptomatic cats experimentally infected with feline immunodeficiency virus. AIDS Res Hum Retrovir 13:1131–1140PubMedCrossRef

Melendez RI, Roman C, Capo-Velez CM, Lasalde-Dominicci JA (2016) Decreased glial and synaptic glutamate uptake in the striatum of HIV-1 gp120 transgenic mice. J Neuro-Oncol 22:358–365

Minassian A, Henry BL, Woods SP, Vaida F, Grant I, Geyer MA, Perry W, Translational Methamphetamine ARCG (2013) Prepulse inhibition in HIV-associated neurocognitive disorders. J Int Neuropsychol Soc 19:709–717PubMedPubMedCentralCrossRef

Mitchell SJ, Morris SR, Kent CK, Stansell J, Klausner JD (2006) Methamphetamine use and sexual activity among HIV-infected patients in care—San Francisco, 2004. AIDS Patient Care STDs 20:502–510PubMedCrossRef

Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Mallory M, Alford M, Masliah E (1995) Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. J Exp Med 181:1551–1556PubMedCrossRef

Nakanishi N, Kang YJ, Tu S, McKercher SR, Masliah E, Lipton SA (2016) Differential effects of pharmacologic and genetic modulation of NMDA receptor activity on HIV/gp120-induced neuronal damage in an in vivo mouse model. J Mol Neurosci 58:59–65PubMedCrossRef

Nath A (2015) Eradication of human immunodeficiency virus from brain reservoirs. J Neuro-Oncol 21:227–234

Nath BM, Schumann KE, Boyer JD (2000) The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol 8:426–431PubMedCrossRef

Okamoto S, Kang YJ, Brechtel CW, Siviglia E, Russo R, Clemente A, Harrop A, McKercher S, Kaul M, Lipton SA (2007) HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. Cell Stem Cell 1:230–236PubMedCrossRef

Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15:1407–1413PubMedPubMedCentralCrossRef

Olmsted RA, Barnes AK, Yamamoto JK, Hirsch VM, Purcell RH, Johnson PR (1989) Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci U S A 86:2448–2452PubMedPubMedCentralCrossRef

Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, Everall IP, Masliah E (2011) Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with roscovitine. Am J Pathol 178:1646–1661PubMedPubMedCentralCrossRef

Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, Henry BL, Zhuang X, Masten VL, Sharp RF, Geyer MA (2009) A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66:1072–1080PubMedPubMedCentralCrossRef

Persidsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet HS, Epstein L, Gelbard H, Flanagan E, Reinhard J, Pirruccello SJ, Gendelman HE (1996) Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol 149:1027–1053PubMedPubMedCentral

Petito CK, Roberts B (1995) Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol 146:1121–1130PubMedPubMedCentral

Poli G, Biswas P, Fauci AS (1994) Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antivir Res 24:221–233PubMedCrossRef

Poluektova L, Meyer V, Walters L, Paez X, Gendelman HE (2005) Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia 52:344–353PubMedCrossRef

Poluektova LY, Munn DH, Persidsky Y, Gendelman HE (2002) Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 168:3941–3949PubMedCrossRef

Potash MJ, Chao W, Bentsman G, Paris N, Saini M, Nitkiewicz J, Belem P, Sharer L, Brooks AI, Volsky DJ (2005) A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A 102:3760–3765PubMedPubMedCentralCrossRef

Raber J, Toggas SM, Lee S, Bloom FE, Epstein CJ, Mucke L (1996) Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase. Virology 226:362–373PubMedCrossRef

Reid W, Sadowska M, Denaro F, Rao S, Foulke J Jr, Hayes N, Jones O, Doodnauth D, Davis H, Sill A, O'Driscoll P, Huso D, Fouts T, Lewis G, Hill M, Kamin-Lewis R, Wei C, Ray P, Gallo RC, Reitz M, Bryant J (2001) An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 98:9271–9276PubMedPubMedCentralCrossRef

Roberts AJ, Maung R, Sejbuk NE, Ake C, Kaul M (2010) Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J Neurosci Methods 186:222–225PubMedCrossRef

Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J, Tyor WR (2009) Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci 29:3948–3955PubMedPubMedCentralCrossRef

Sas AR, Bimonte-Nelson HA, Tyor WR (2007) Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of interferon-alpha in the brain. AIDS 21:2151–2159PubMedCrossRef

Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA (2007) Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 21:1877–1886PubMedCrossRef

Schwartz L, Major EO (2006) Neural progenitors and HIV-1-associated central nervous system disease in adults and children. Curr HIV Res 4:319–327PubMedCrossRef

Shi B, De GU, He J, Wang S, Lorenzo A, Busciglio J, Gabuzda D (1996) Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest 98:1979–1990PubMedPubMedCentralCrossRef

Soontornniyomkij V, Kesby JP, Morgan EE, Bischoff-Grethe A, Minassian A, Brown GG, Grant I, Translational Methamphetamine ARCG (2016) Effects of HIV and methamphetamine on brain and behavior: evidence from human studies and animal models. J NeuroImmune Pharmacol 11:495–510PubMedPubMedCentralCrossRef

Steiner JP, Bachani M, Wolfson-Stofko B, Lee MH, Wang T, Li G, Li W, Strayer D, Haughey NJ, Nath A (2015) Interaction of paroxetine with mitochondrial proteins mediates neuroprotection. Neurotherapeutics 12:200–216PubMedCrossRef

Thaney VE, O’Neill AM, Hoefer MM, Maung R, Sanchez AB, Kaul M (2017) IFNβ protects neurons from damage in a murine model of HIV-1 associated brain injury. Sci Rep 7:46514PubMedPubMedCentralCrossRef

Thomas FP, Chalk C, Lalonde R, Robitaille Y, Jolicoeur P (1994) Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol 68:7099–7107PubMedPubMedCentral

Toggas SM, Masliah E, Mucke L (1996) Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res 706:303–307PubMedCrossRef

Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367:188–193PubMedCrossRef

Toggas SM, Mucke L (1996) Transgenic models in the study of AIDS dementia complex. Curr Top Microbiol Immunol 206:223–241PubMed

Toggas SM, Mucke L (1998) Transgenic models to assess the pathogenic potential of viral products in HIV-1-associated CNS disease. In: Lipton SA, Epstein L, Swindells S (eds) The neurology of AIDS. Gendelman HE. Chapman & Hall, New York, pp 156–167

Toneatto S, Finco O, van der PH, Abrignani S, Annunziata P (1999) Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 13:2343–2348PubMedCrossRef

Tran PB, Ren D, Miller RJ (2005) The HIV-1 coat protein gp120 regulates CXCR4-mediated signaling in neural progenitor cells. J Neuroimmunol 160:68–76PubMedCrossRef

Tyor WR, Power C, Gendelman HE, Markham RB (1993) A model of human immunodeficiency virus encephalitis in SCID mice. Proc Natl Acad Sci U S A 90:8658–8662PubMedPubMedCentralCrossRef

Urbina A, Jones K (2004) Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 38:890–894PubMedCrossRef

Van Duyne R, Pedati C, Guendel I, Carpio L, Kehn-Hall K, Saifuddin M, Kashanchi F (2009) The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 6:76PubMedPubMedCentralCrossRef

Wang EJ, Sun J, Pettoello-Mantovani M, Anderson CM, Osiecki K, Zhao ML, Lopez L, Lee SC, Berman JW, Goldstein H (2003) Microglia from mice transgenic for a provirus encoding a monocyte-tropic HIV type 1 isolate produce infectious virus and display in vitro and in vivo upregulation of lipopolysaccharide-induced chemokine gene expression. AIDS Res Hum Retrovir 19:755–765PubMedCrossRef

Wang RG, Kaul M, Zhang DX (2012) Interferon-stimulated gene 15 as a general marker for acute and chronic neuronal injuries. Sheng Li Xue Bao 64:577–583PubMed

Williams R, Bokhari S, Silverstein P, Pinson D, Kumar A, Buch S (2008) Nonhuman primate models of neuroAIDS. J Neuro-Oncol 14:292–300

Wilson ME, Dimayuga FO, Reed JL, Curry TE, Anderson CF, Nath A, Bruce-Keller AJ (2006) Immune modulation by estrogens: role in CNS HIV-1 infection. Endocrine 29:289–297PubMedCrossRef

Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, Paulino A, Gonzales T, Overk CR, Patrick C, Rockenstein E, Masliah E (2014) Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. Br J Pharmacol 171:5757–5773PubMedPubMedCentralCrossRef

Wyss-Coray T, Masliah E, Toggas SM, Rockenstein EM, Brooker MJ, Lee HS, Mucke L (1996) Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. J Clin Invest 97:789–798PubMedPubMedCentralCrossRef

Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT (2004) Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363:2040–2046PubMedCrossRef

Young JW, Minassian A, Geyer MA (2016) Locomotor profiling from rodents to the clinic and back again. Curr Top Behav Neurosci 28:287–303PubMedCrossRef

Zhou D, Masliah E, Spector SA (2011) Autophagy is increased in postmortem brains of persons with HIV-1-associated encephalitis. J Infect Dis 203:1647–1657PubMedPubMedCentralCrossRef

Title: Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research
Authors: Victoria E. Thaney
Ana B. Sanchez
Jerel A. Fields
Arpi Minassian
Jared W. Young
Ricky Maung
Marcus Kaul
Publication date: 01-04-2018
Publisher: Springer International Publishing
Published in: Journal of NeuroVirology / Issue 2/2018
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-017-0584-2

At a glance: The STEP trials

Springer Medicine

Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model

A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments

Evolution of the HIV-1 transgenic rat: utility in assessing the progression of HIV-1-associated neurocognitive disorders

Changing clinical phenotypes of HIV-associated neurocognitive disorders

Optimizing animal models for HIV-associated CNS dysfunction and CNS reservoir research

HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency